Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer

SCRI Development Innovations, LLC27 enrolled

Overview

With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor (EGFR)-wild type patients that gain benefit from erlotinib and assess the clinical characteristics that are associated with erlotinib-responders. Additionally, biopsy specimens from enrolled patient cases that are EGFR-wt will be evaluated via exploratory genetic analysis for correlated markers.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Non Small Cell Lung Cancer

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must have had NSCLC. * Patients must have received erlotinib (single-agent) for six months or longer for NSCLC in the second/third line setting or as maintenance therapy. * Patients must have tissue available for EGFR-mutation status testing (if not previously performed) or EGFR-mutation status test results available. * Patients must have tissue available for exploratory genetic analysis. * Patients must have all clinical information, treatment response data and outcomes data available for review. * Patients must be deceased.

Locations (1)

Tennessee Oncology, PLLC

Nashville, Tennessee, United States

Outcomes

Primary Outcomes

demographics

To describe patient demographic characteristics of patients with erlotinib (single-agent) treatment duration of six months or longer, including patients who are EGFR-wt. Demographic characteristics include age, race,ethnicity, date of initial diagnosis, age at initial diagnosis, location of biopsy at diagnosis, extent of disease with description and location of metastatic sites, histology,and smoking history.

Time frame: 24 months

treatment characteristics

To describe patient treatment and characteristics of patients with erlotinib (single-agent) treatment duration of six months or longer, including patients who are EGFR-wt. Including number and kind of prior therapies, disease stage at initial diagnosis, sites of metastasis at time of erlotinib treatment, prior surgery, and radiation.

Time frame: 24 months

outcome characteristics

To describe patient outcome characteristics of patients with erlotinib (single-agent) treatment duration of six months or longer, including patients who are EGFR-wt including the reason for discontinuing erlotinib treatment, best response to erlotinib treatment and did patient receive any dose modifications while receiving erlotinib treatment.

Time frame: 24 months

Secondary Outcomes

Biomarker characteristics

To explore biomarker (BM) characteristics of EGFR-wt erlotinib responders.

Time frame: 24 months

Exploratory genetic analysis

Biopsy specimens from enrolled patient cases who are EGFR-wt will be evaluated via exploratory genetic analysis for correlated biomarkers.

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.